overall risk for CHD. 8 The Framingham equation is the principal instrument for risk assessment. 9 While the Framingham equation has good predictive ability, it does not account for CKD or race. The model has performed well in multiple diverse populations, but distinguishes poorly among those who do and do not develop CHD in minority patients and those with CKD. [9] [10] [11] [12] In 4 separate analyses, addition of CKD to the Framingham equation did not improve overall predictive ability. [13] [14] [15] Limitations of these studies include a relatively small number of participants with CKD and, in one, analysis was limited to improvement in stratification without assessment of reclassification. 13, 16, 17 A well-powered analysis of the addition of both CKD and race to the Framingham equation may reveal a model with improved ability to discriminate between those who do and do not develop CHD. More accurate classification of patients into risk categories will allow for more appropriate therapeutic targeting and management of CHD risk.
The objective of the current study was to evaluate whether addition of CKD and stratification by race improves the ability of the Framingham equation to predict CHD.
Methods
The rationale, design, and baseline characteristics of the ALLHAT have been published. 18, 19 Participants were men and women 55 years or older who had hypertension with at least 1 additional risk factor for CHD. This study was supported by contract NO1-HC-35130 with the National Heart, Lung, and Blood Institute and by a Career Development Award to Dr Drawz (K23DK087919).
Exclusion criteria
For this analysis, all participants were included with the following exceptions: age greater than 74 years; missing baseline data for high-density lipoprotein (HDL) or both calculated lowdensity lipoprotein (cLDL) and total cholesterol; participants with a history of CHD as defined by a response to a single question on the baseline questionnaire. On the baseline questionnaire, CHD was defined as a history of MI, primary cardiac arrest, coronary revascularization, angina, coronary stenosis greater than 50%, or reversible coronary perfusion defect on noninvasive cardiac testing. Eligible participants were randomly assigned to a developmental (two thirds) or validation (one third) sample.
Baseline measurements
Before initiating study medications, participants had blood drawn for the baseline measurement of fasting glucose, total cholesterol, HDL cholesterol, triglycerides, and creatinine. LDL cholesterol was calculated using the Friedewald formula unless triglyceride levels were greater than 400 mg/dl in which case lipoprotein ultracentrifugation was performed on fasting specimens. Serum creatinine was measured in a central laboratory and comparison with the Modification of Diet in Renal Disease (MDRD) laboratory revealed that no further calibration was required. 20 Estimated glomerular filtration rate (eGFR) was calculated according to the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation. 21 Secondary analyses were conducted with eGFR calculated according to the simplified MDRD study equation. 22 ). 23 Patients with a serum creatinine level of ≥2 mg/dL were excluded. Therefore, the percentage of patients with severe CKD (estimated eGFR ≤29 mL/min per 1.73 m 2 ) at baseline was very small (0.6%); these participants were included in the moderate or severe CKD category (eGFR b60 mL/min per 1.73 m 2 ). 2, 24 A participant was considered to have diabetes if a history of diabetes was noted on the baseline questionnaire or the participant had a baseline fasting glucose ≥126 mg/dL. Baseline blood pressures were based on the average of 2 seated measurements. 18 
Primary outcome
The primary outcome for this study was CHD, which included fatal CHD, nonfatal MI, coronary revascularization, or hospitalized angina. 25 Coronary revascularization included coronary artery bypass grafting, percutaneous angioplasty, coronary stents, and atherectomy. This outcome was chosen because it was a major prespecified secondary ALLHAT outcome and to be consistent with the Framingham "hard" CHD outcome: recognized and unrecognized MI, coronary insufficiency, and CHD death. 9 
Statistical analysis
Cutoffs for total cholesterol, cLDL, HDL, and age were used in this analysis to be consistent with the original Framingham equation. 9 Systolic blood pressure and diastolic blood pressure were classified according to guidelines from The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7) and the original Framingham blood pressure categories (see Table I ). If classification based on systolic and diastolic pressures differed, subjects were assigned to the higher category (e.g., a subject with a blood pressure of 155/80 mm Hg would be assigned to the 140 to 159/90 to 99 mm Hg group). Race was categorized as self-reported black or non-black. Hispanics were eligible for inclusion in either the black or non-black category.
Eligible participants were randomly assigned to a developmental (two-thirds) or validation (one-third) sample. Cox proportional hazards regression were performed on the developmental sample to evaluate the relationship between CHD and age, smoking status, diabetes, blood pressure, total cholesterol, HDL, and eGFR. Tests for interaction were performed. Four-and 6-year follow-up were used in the proportional hazards model and adapted to provide a 5-year CHD risk estimate. A new risk score based on the Cox model for the developmental sample was calculated for all participants, irrespective of race or eGFR (model 1). A separate risk score was then developed with inclusion of CKD and stratification by race (model 2). Treatment arms were entered as covariates.
The C-statistic for the new scores and the Framingham equation 11 were compared in the validation sample to evaluate discrimination. 26 Reclassification of participants into higher and lower risk categories between models 1 and 2 in the validation sample was evaluated by calculating net reclassification improvement (NRI). 16 NRI was calculated separately for black and non-black men and women. Model calibration was evaluated by graphing the predicted and actual risk by deciles of ALLHAT risk (model 2).
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Results
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,418 participants were randomized and 19,811 met inclusion and exclusion criteria for the present analyses (see Figure 1 ). Baseline characteristics of participants in the developmental sample (n = 13,207) stratified by black/non-black and sex are shown in Table I (online  table I for the validation sample). Age-adjusted 5 year rates of CHD, calculated using the developmental sample and separated by gender and race, are shown in online Table II . Rates were higher in men than women for both Blacks and Non-Blacks over nearly all categories of blood pressure, total cholesterol, HDL, and eGFR.
The β-coefficients used to calculate the 5-year probability of CHD for the validation sample and baseline survival at 5 years, are shown in Table II. Note that model 1 does not include the eGFR variable and therefore the β-coefficients are not calculated. In addition, additional calculations based on stratification by black/non-black are needed for model 2.
C-statistics in the validation cohort are presented in Table III for the Framingham model 11 and the ALLHAT model that includes CKD and stratification by race (model 2). The C-statistics for both models ranged from as low as 0.428 to 0.693, indicating relatively low predictive ability. C-statistics were higher for women than men in both black and non-black participants. Cstatistics were lower for blacks compared to non-blacks. Only among non-black women was there a significant difference between the Framingham model and the ALLHAT model. In this subgroup, the C-statistic was higher for the Framingham model. Predicted and actual event rates for black females in the validation cohort by deciles of predicted risk based on ALLHAT model 2 are shown in Figure 2 . Similar graphs for other subgroups based on race, sex, and kidney function are available online. Results were unchanged in secondary analyses with eGFR calculated using the MDRD formula. Table IV shows participants categorized by ALLHAT models 1 and 2 into risk categories of b10%, 10% to b20% and ≥20% for 5-year risk of CHD. Each cell in Table IV refers to the number of participants who are categorized by model 1 and model 2 into the corresponding risk categories. For instance, the cell in the 5th row and first column of Five-year CHD event rates among black females (n = 1495) in the validation sample by deciles of predicted risk based on ALLHAT model 2.
model including CKD and race to classify participants as compared to the model without these variables. This assessment was done for both men and women and blacks and non-blacks separately. None of the NRI values were significant, indicating no improvement in risk classification with the addition of CKD and stratification by race.
Discussion
This study shows that the addition of CKD and race to the Framingham equation does not improve discrimina- ⁎ Net reclassification improvement assesses the ability of the model including chronic kidney disease (CKD) and race to classify participants as compared to the model without these variables.
tion (C statistic) or risk classification (NRI) among hypertensive subjects. These findings are important as they provide the first well-powered analysis of the impact of adding CKD and race to the Framingham equation. Similar results were observed across all subgroups by race and sex and when analyses were restricted to only those subjects with CKD. These findings are consistent with previous studies evaluating the addition of CKD to the Framingham equation. In a population derived from ARIC and CHS, addition of CKD to the Framingham equation did not increase overall predictive ability. 13 Limitations of the ARIC/CHS study were the small number of participants with CKD and analyses were restricted to improvement in discrimination with no consideration for reclassification. 16, 17 Similarly, in a large cohort from Iceland, the addition of CKD resulted in a slight improvement in Harrell's C index but no improvement classification despite the inclusion of proteinuria in the definition of CKD.
14 Among subjects enrolled in ONTARGET and TRANSCEND, eGFR and albuminuria were associated with cardiovascular outcomes but no improvement in risk classification was observed when these variables were added to traditional risk factors. 15 Finally, in the Rotterdam study, CKD was associated with CHD in multivariable models; however, addition of CKD to a model including the Framingham variables did not increase the C-statistic or result in a positive NRI. 27 Despite the moderate to poor performance of the Framingham equation among minorities, the impact on risk stratification of the addition of race to the Framingham equation had not been evaluated in a validation cohort. 11 Multiple studies have evaluated the interaction between race and various risk factors for CHD. In ARIC, hypertension was found to be a more powerful predictor of CHD in Black women, while diabetes was a greater risk factor in White compared to Black women. 10 In addition, data from NHANES II and a pooled analysis of data from ARIC, CHS, Framingham, and the Framingham Offspring study revealed that CKD is a greater risk factor for cardiovascular disease in blacks than whites. 3, 5 Nevertheless, in the current study, stratification by race did not lead to improved discrimination or risk reclassification among blacks or non-blacks.
In this large hypertensive cohort, C-statistics for the Framingham equation ranged from 0.58 to 0.68 in subgroups by race and gender among all participants and from 0.53 to 0.69 in participants with CKD. Cstatistics were consistently higher in women compared to men and in non-blacks compared to blacks. These results are consistent with a previous validation study conducted in multiple different ethnic groups where C-statistics were higher in women and whites. 11 The poor performance of the Framingham equation in ALLHAT corroborates previous reports of poor predictive ability among hypertensive subjects enrolled in clinical trials. 28, 29 The C-statistic for cardiovascular disease was only 0.66 among subjects in the INSIGHT trial and ranged from 0.53 for coronary heart disease death to 0.58 for MI in the Second Australian National Blood Pressure Study. 28, 29 The poor performance of the Framingham equation in these hypertension trials may be due to the advanced age of the subjects, differences between subjects included in clinical trials and the general population, and better blood pressure control in a trial setting than in general practice. 30 Additionally, the prevalence of cardiovascular risk factors is changing over time and has coincided with decreased incidence of cardiovascular disease. 31 Therefore, the Framingham equation, derived from a cohort based on a baseline examination in the early 1970s, may not predict disease as accurately in the 21st century.
Our study has a number of limitations to consider. First, the ALLHAT cohort includes only high risk hypertensive subjects. However, the results are clinically relevant given the high prevalence of hypertension in the population; over one-half of patients 60 to 69 years old and three-fourths of patients aged 70 years and older have hypertension. 32 Another limitation is that our study only includes patients age 55 years and older. Our analysis of CKD is limited to serum creatinine as ALLHAT did not evaluate for proteinuria, a known risk factor for all-cause mortality and cardiovascular disease. 33 Additionally, most of the patients with CKD in ALLHAT had stage 3A CKD, which may carry less significance as a risk factor for cardiovascular disease than more advanced CKD. 4 Because prior reports indicated the impact of various risk factors differ by race, ALLHAT models were developed with stratification by race, which may be a surrogate for socioeconomic status. Given the poor performance of the prediction models in all subgroups, it is unlikely that including socioeconomic status would improve predictive ability.
Strengths of our study include a large sample size. The ALLHAT cohort was chosen in part because of the large number of Blacks and patients with CKD (5,099 and 1,832 in the developmental cohort, respectively). Combined CHD was a primary outcome and was therefore carefully adjudicated. Finally, our analysis included not only a comparison of discrimination, but also an evaluation of the reclassification of subjects using the new risk model. This evaluation is more sensitive to model improvement and more clinically relevant.
In conclusion, CKD has consistently been shown to be an independent risk factor for CHD. However, the current study confirms previous reports that addition of CKD to the Framingham equation does not improve prediction of CHD. In addition, stratification by race does not improve prediction of CHD, even among Blacks. Further work is necessary to develop more accurate prediction models in hypertensive patients, especially for men and Blacks.
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